Neutropénie fébrile induite par la chimiothérapie : Questions médicales fréquentes
Nom anglais: Chemotherapy-Induced Febrile Neutropenia
Descriptor UI:D064146
Tree Number:C15.378.553.546.184.564.750.500
Termes MeSH sélectionnés :
Data Systems
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Neutropénie fébrile induite par la chimiothérapie : Questions médicales les plus fréquentes",
"headline": "Neutropénie fébrile induite par la chimiothérapie : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Neutropénie fébrile induite par la chimiothérapie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-16",
"dateModified": "2025-05-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Neutropénie fébrile induite par la chimiothérapie"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Neutropénie fébrile",
"url": "https://questionsmedicales.fr/mesh/D064147",
"about": {
"@type": "MedicalCondition",
"name": "Neutropénie fébrile",
"code": {
"@type": "MedicalCode",
"code": "D064147",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.553.546.184.564.750"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Neutropénie fébrile induite par la chimiothérapie",
"alternateName": "Chemotherapy-Induced Febrile Neutropenia",
"code": {
"@type": "MedicalCode",
"code": "D064146",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Matti Aapro",
"url": "https://questionsmedicales.fr/author/Matti%20Aapro",
"affiliation": {
"@type": "Organization",
"name": "Cancer Centre, Clinique de Genolier, Genolier, Switzerland."
}
},
{
"@type": "Person",
"name": "Shinsuke Sasada",
"url": "https://questionsmedicales.fr/author/Shinsuke%20Sasada",
"affiliation": {
"@type": "Organization",
"name": "Department of Breast Surgery, Hiroshima University Hospital, Hiroshima, Japan. shsasada@hiroshima-u.ac.jp."
}
},
{
"@type": "Person",
"name": "Hiromi Nishi",
"url": "https://questionsmedicales.fr/author/Hiromi%20Nishi",
"affiliation": {
"@type": "Organization",
"name": "Department of General Dentistry, Hiroshima University Hospital, Hiroshima, Japan."
}
},
{
"@type": "Person",
"name": "Yuri Kimura",
"url": "https://questionsmedicales.fr/author/Yuri%20Kimura",
"affiliation": {
"@type": "Organization",
"name": "Department of Breast Surgery, Hiroshima University Hospital, Hiroshima, Japan."
}
},
{
"@type": "Person",
"name": "Akiko Emi",
"url": "https://questionsmedicales.fr/author/Akiko%20Emi",
"affiliation": {
"@type": "Organization",
"name": "Department of Breast Surgery, Hiroshima University Hospital, Hiroshima, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Validation of the diagnostic efficacy of O-RADS in adnexal masses.",
"datePublished": "2023-09-21",
"url": "https://questionsmedicales.fr/article/37735610",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-42836-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "The diagnostic efficacy and inappropriate biopsy rate of ACR TI-RADS and ATA guidelines for thyroid nodules in children and adolescents.",
"datePublished": "2023-03-27",
"url": "https://questionsmedicales.fr/article/37051202",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2023.1052945"
}
},
{
"@type": "ScholarlyArticle",
"name": "Investigation of a Complex Reaction Pathway Network of Isobutane/2-Butene Alkylation by CGC-FID and CGC-MS-DS.",
"datePublished": "2022-10-13",
"url": "https://questionsmedicales.fr/article/36296457",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules27206866"
}
},
{
"@type": "ScholarlyArticle",
"name": "Thy-Wise: An interpretable machine learning model for the evaluation of thyroid nodules.",
"datePublished": "2022-09-12",
"url": "https://questionsmedicales.fr/article/36095154",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ijc.34248"
}
},
{
"@type": "ScholarlyArticle",
"name": "O-RADS MRI After Initial Ultrasound for Adnexal Lesions:",
"datePublished": "2022-08-17",
"url": "https://questionsmedicales.fr/article/35975887",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2214/AJR.22.28084"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Hémopathies et maladies lymphatiques",
"item": "https://questionsmedicales.fr/mesh/D006425"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hémopathies",
"item": "https://questionsmedicales.fr/mesh/D006402"
},
{
"@type": "ListItem",
"position": 4,
"name": "Troubles leucocytaires",
"item": "https://questionsmedicales.fr/mesh/D007960"
},
{
"@type": "ListItem",
"position": 5,
"name": "Leucopénie",
"item": "https://questionsmedicales.fr/mesh/D007970"
},
{
"@type": "ListItem",
"position": 6,
"name": "Agranulocytose",
"item": "https://questionsmedicales.fr/mesh/D000380"
},
{
"@type": "ListItem",
"position": 7,
"name": "Neutropénie",
"item": "https://questionsmedicales.fr/mesh/D009503"
},
{
"@type": "ListItem",
"position": 8,
"name": "Neutropénie fébrile",
"item": "https://questionsmedicales.fr/mesh/D064147"
},
{
"@type": "ListItem",
"position": 9,
"name": "Neutropénie fébrile induite par la chimiothérapie",
"item": "https://questionsmedicales.fr/mesh/D064146"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Neutropénie fébrile induite par la chimiothérapie - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Neutropénie fébrile induite par la chimiothérapie",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Neutropénie fébrile induite par la chimiothérapie",
"description": "Comment diagnostiquer la neutropénie fébrile ?\nQuels tests sont nécessaires pour le diagnostic ?\nQuel seuil de neutrophiles indique une neutropénie ?\nQuand doit-on suspecter une neutropénie fébrile ?\nQuels signes cliniques peuvent alerter ?",
"url": "https://questionsmedicales.fr/mesh/D064146?mesh_terms=Data+Systems&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Neutropénie fébrile induite par la chimiothérapie",
"description": "Quels sont les symptômes de la neutropénie fébrile ?\nLa neutropénie fébrile cause-t-elle des douleurs ?\nComment se manifeste la fièvre dans cette condition ?\nY a-t-il des symptômes cutanés associés ?\nLes symptômes varient-ils selon les patients ?",
"url": "https://questionsmedicales.fr/mesh/D064146?mesh_terms=Data+Systems&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Neutropénie fébrile induite par la chimiothérapie",
"description": "Comment prévenir la neutropénie fébrile ?\nLes patients doivent-ils éviter certains aliments ?\nQuelles mesures d'hygiène sont recommandées ?\nLes vaccinations sont-elles importantes ?\nComment gérer les contacts avec des malades ?",
"url": "https://questionsmedicales.fr/mesh/D064146?mesh_terms=Data+Systems&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Neutropénie fébrile induite par la chimiothérapie",
"description": "Quel est le traitement principal de la neutropénie fébrile ?\nQuand administrer des antibiotiques ?\nQuels facteurs de croissance sont utilisés ?\nLa transfusion de plaquettes est-elle nécessaire ?\nComment surveiller l'efficacité du traitement ?",
"url": "https://questionsmedicales.fr/mesh/D064146?mesh_terms=Data+Systems&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Neutropénie fébrile induite par la chimiothérapie",
"description": "Quelles sont les complications possibles ?\nLa neutropénie fébrile peut-elle être mortelle ?\nQuels types d'infections sont fréquents ?\nComment le sepsis se développe-t-il ?\nY a-t-il des risques de complications à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D064146?mesh_terms=Data+Systems&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Neutropénie fébrile induite par la chimiothérapie",
"description": "Quels sont les principaux facteurs de risque ?\nLes antécédents médicaux influencent-ils le risque ?\nLe sexe du patient joue-t-il un rôle ?\nLes traitements antérieurs affectent-ils le risque ?\nL'état nutritionnel influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D064146?mesh_terms=Data+Systems&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la neutropénie fébrile ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur une numération sanguine et la présence de fièvre."
}
},
{
"@type": "Question",
"name": "Quels tests sont nécessaires pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analyses sanguines et des cultures microbiologiques sont essentielles."
}
},
{
"@type": "Question",
"name": "Quel seuil de neutrophiles indique une neutropénie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une numération inférieure à 1500 neutrophiles par microlitre est considérée comme neutropénie."
}
},
{
"@type": "Question",
"name": "Quand doit-on suspecter une neutropénie fébrile ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "En cas de fièvre supérieure à 38°C chez un patient sous chimiothérapie."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques peuvent alerter ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des frissons, une fatigue extrême et des infections cutanées peuvent alerter."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de la neutropénie fébrile ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, frissons, infections fréquentes et fatigue intense sont courants."
}
},
{
"@type": "Question",
"name": "La neutropénie fébrile cause-t-elle des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des douleurs abdominales ou thoraciques dues à des infections."
}
},
{
"@type": "Question",
"name": "Comment se manifeste la fièvre dans cette condition ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La fièvre est souvent supérieure à 38°C et peut être persistante."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées ou des ulcères peuvent apparaître en raison d'infections."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les patients ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'état immunitaire et des infections."
}
},
{
"@type": "Question",
"name": "Comment prévenir la neutropénie fébrile ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut l'utilisation de facteurs de croissance et une bonne hygiène."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains aliments ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter les aliments crus ou mal cuits pour réduire le risque d'infection."
}
},
{
"@type": "Question",
"name": "Quelles mesures d'hygiène sont recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Se laver les mains fréquemment et éviter les foules sont recommandés."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations doivent être à jour pour prévenir les infections."
}
},
{
"@type": "Question",
"name": "Comment gérer les contacts avec des malades ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les contacts avec des personnes malades est crucial pour la prévention."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal de la neutropénie fébrile ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal inclut des antibiotiques et des facteurs de croissance des neutrophiles."
}
},
{
"@type": "Question",
"name": "Quand administrer des antibiotiques ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antibiotiques doivent être administrés dès que la neutropénie fébrile est suspectée."
}
},
{
"@type": "Question",
"name": "Quels facteurs de croissance sont utilisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le G-CSF (facteur de stimulation des colonies de granulocytes) est couramment utilisé."
}
},
{
"@type": "Question",
"name": "La transfusion de plaquettes est-elle nécessaire ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut être nécessaire si le patient présente une thrombopénie sévère."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La numération sanguine doit être surveillée régulièrement pour évaluer la réponse."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections graves, des sepsis et des hospitalisations prolongées."
}
},
{
"@type": "Question",
"name": "La neutropénie fébrile peut-elle être mortelle ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être mortelle si des infections ne sont pas traitées rapidement."
}
},
{
"@type": "Question",
"name": "Quels types d'infections sont fréquents ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les infections bactériennes et fongiques sont les plus fréquentes chez ces patients."
}
},
{
"@type": "Question",
"name": "Comment le sepsis se développe-t-il ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le sepsis peut se développer à partir d'infections non traitées en raison de la neutropénie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications à long terme peuvent inclure des problèmes immunitaires persistants."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent le type de chimiothérapie et l'âge avancé du patient."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies hématologiques augmentent le risque de neutropénie."
}
},
{
"@type": "Question",
"name": "Le sexe du patient joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le sexe n'a pas d'impact significatif sur le risque de neutropénie fébrile."
}
},
{
"@type": "Question",
"name": "Les traitements antérieurs affectent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements antérieurs peuvent sensibiliser le patient à la neutropénie."
}
},
{
"@type": "Question",
"name": "L'état nutritionnel influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un état nutritionnel déficient peut augmenter le risque d'infections et de neutropénie."
}
}
]
}
]
}
The aim of this study was to validate the performance of the Ovarian-Adnexal Reporting and Data Systems (O-RADS) series models proposed by the American College of Radiology (ACR) in the preoperative d...
This study is aimed at evaluating the diagnostic efficacy and unnecessary fine-needle aspiration (FNA) rate of ultrasound-based risk stratification for thyroid nodules in the American College of Radio...
Children and adolescents with pathology confirmed thyroid nodules were retrospectively included in this study. A total of 217 thyroid nodules from multicenter of Union Medical College Hospital, China ...
Among all thyroid nodules, 139 nodules were malignant, and 78 nodules were benign. Choosing ATA high suspicion and ACR TI-RADS TR5 as benign and malignant cut-off points, the area under the curve and ...
This study indicated that both ATA and ACR TI-RADS risk stratification systems could provide a feasible differential diagnosis of benign and malignant thyroid nodules, while the ACR risk stratificatio...
The mechanism of reaction in isobutane/2-butene alkylation systems is extremely complicated, accompanied by numerous side reactions. Therefore, a comprehensive understanding of the reaction pathways i...
Current risk stratification systems for thyroid nodules suffer from low specificity and high biopsy rates. Recently, machine learning (ML) is introduced to assist thyroid nodule diagnosis but lacks in...
The Ovarian-Adnexal Reporting and Data System (O-RADS) ultrasound (US) and MRI risk stratification systems were developed by an international group of experts in adnexal imaging to aid radiologists in...
Ultrasound-based risk stratification systems (Thyroid Imaging Reporting and Data Systems (TIRADSs)) of thyroid nodules (TNs) have been implemented in clinical practice worldwide based on their high pe...
A search was conducted on PubMed and Embase until June 2023. Original studies that sequentially assessed TNs using TIRADSs, regardless of FNAC indication, were selected. General study characteristics ...
Seven studies, reporting a total of 41,332 TNs, were included in the analysis. The prevalence of ACR-TIRADS 1-2 was significantly higher than that of EU-TIRADS 2 and K-TIRADS 2, with no significant di...
ACR-, EU-, and K-TIRADS assess TNs similarly across their categories, with slight differences in low-risk classifications. Despite this, focusing on cancer risk estimation, the three TIRADSs assess TN...
As the incidence of hepatocellular carcinoma (HCC) and subsequent treatments with liver-directed therapies rise, the complexity of assessing lesion response has also increased. The Liver Imaging Repor...
To conduct a nonsystematic review of the existing literature to investigate the role of Magnetic Resonance Imaging (MRI) in urothelial carcinomas (UCs)....
Imaging is becoming progressively more crucial in local and distant staging of UCs, especially in cases of bladder cancer (BCa). The primary objective of imaging in patients with BCa is to detect lesi...
The applicability of MRI in the management of UCs has been investigated, particularly focusing on the new evidence on multiparametric MRI (mpMRI) of the bladder and Vesical Imaging-Reporting And Data ...
NEXT collaboration detectors are based on energy measured by an array of photomultipliers (PMT) and topological event filtering based on an array of silicon photomultipliers (SiPMs). The readout of th...
Healthcare systems data (HSD) has the potential to optimise the efficiency of randomised controlled trials (RCTs), by decreasing trial-specific data demands. Therefore, the use of HSD in trials is exp...
We identified a cohort of RCTs within the NIHR Journals Library that commenced after 2019 and were described as being in progress on 6 June 2022. Details on the source and use of HSD were extracted fr...
Of the 84 eligible studies, 52 (62%) planned to use HSD and 79 (94%) planned to collect PROs. The number of RCTs planning to use HSD for at least one outcome was 28 (54%) with 24 of these planning to ...
HSD is being used in around two thirds of the studies but cannot yet be used to support PRO data collection within the cohort we examined. Comparison with an earlier cohort demonstrates an increase in...